Siddiqi Shan H, Creech Mary L, Black Kevin J
Department of Psychiatry, Washington University School of Medicine , St. Louis, MO , USA.
Department of Neurology, Washington University School of Medicine , St. Louis, MO , USA.
PeerJ. 2015 Aug 27;3:e1198. doi: 10.7717/peerj.1198. eCollection 2015.
Intravenous levodopa has been used in a multitude of research studies due to its more predictable pharmacokinetics compared to the oral form, which is used frequently as a treatment for Parkinson's disease (PD). Levodopa is the precursor for dopamine, and intravenous dopamine would strongly affect vascular tone, but peripheral decarboxylase inhibitors are intended to block such effects. Pulse and blood pressure, with orthostatic changes, were recorded before and after intravenous levodopa or placebo-after oral carbidopa-in 13 adults with a chronic tic disorder and 16 tic-free adult control subjects. Levodopa caused no statistically or clinically significant changes in blood pressure or pulse. These data add to previous data that support the safety of i.v. levodopa when given with adequate peripheral inhibition of DOPA decarboxylase.
与常用于治疗帕金森病（PD）的口服左旋多巴相比，静脉注射左旋多巴因其药代动力学更可预测，已被用于众多研究中。左旋多巴是多巴胺的前体，静脉注射多巴胺会强烈影响血管张力，但外周脱羧酶抑制剂旨在阻断此类作用。在13名患有慢性抽动障碍的成年人和16名无抽动的成年对照受试者中，在静脉注射左旋多巴或口服卡比多巴后服用安慰剂前后，记录了脉搏和血压以及体位性变化。左旋多巴在血压或脉搏方面未引起统计学或临床上的显著变化。这些数据补充了先前的数据，支持在给予足够外周多巴脱羧酶抑制的情况下静脉注射左旋多巴的安全性。
